News

Haggling about location ended
Enlarge image

PoliticsEUFranceGermanyUK

Haggling about location ended

03.07.2012 - No chunks for noone, nuggets for Paris, London and Munich. The EU commission finally agreed on the setting for the proposed EU patents court.

On 29 June at the European Council in Brussels, Belgium, the EU heads of state agreed on a plan to implement a so far only proposed EU patents court which now could become functional in 2014. Currently, the European Patent Office (EPO) has responsibility for the examination and grant of 'European' patents, but once those patents are granted they become an individual patent in each country selected by the proprietor. Should the proprietors of the patents wish to enforce them they must do so in each country individually. The new court will maintain divisions in three different countries with France coming up with the most important one. The central division of the Court of First Instance (CFI) of the Unified Patent Court (UPC) will be - together with the CFI-president's office in Paris. Subdivisions handling chemistry and pharmaceutics industry as well as mechanical engineering will be installed in London and Munich, respectfully. Although Munich has already the headquarters of the EPO the heavy lobbying for Munich as the place for a EU patents court did not suceed in the end.

The long awaited EU patents court will facilitate the introduction of patents with a unitary effect across the member states. However, Italy and Spain are excluded so far because they diagree with the current language arrangements. Uninvolved of the patents court agreement the unitary patent itself has to be approved by the European Parliament and the Council of Ministers. The crucial step is the vote in the parliament on 3 and 4 July. The then following Council approval is merely a formality.

http://www.european-biotechnology-news.com/news/news/2012-03/haggling-about-location-ended.html

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ZEALAND PHARMA (DK)130.50 DKK11.06%

FLOP

  • BIOFRONTERA (D)2.84 EUR-4.70%
  • CHRONTECH PHARMA (S)0.34 SEK-2.86%
  • PHOTOCURE (N)41.50 NOK-2.35%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • GALAPAGOS (B)52.23 EUR30.5%
  • NICOX (F)10.89 EUR26.3%

FLOP

  • MOBERG PHARMA (S)38.70 SEK-21.8%
  • BIONOR PHARMA (N)0.70 NOK-21.3%
  • BIOCARTIS GROUP NV (B)8.32 EUR-18.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.50 SEK1853.6%
  • NICOX (F)10.89 EUR485.5%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.95 SEK-87.8%
  • BB BIOTECH (D)44.62 EUR-84.6%
  • BIOTEST (D)17.10 EUR-77.8%

No liability assumed, Date: 26.05.2016